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Background: GNE myopathy is a slowly progressive autosomal recessive myopathy caused by mutations in the
GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase) gene. This study aimed to (1) develop
a nationwide patient registry for GNE myopathy in order to facilitate the planning of clinical trials and recruitment
of candidates, and (2) gain further insight into the disease for the purpose of improving therapy and care.
Methods: Medical records of genetically-confirmed patients with GNE myopathy at the National Center Hospital of
the National Center of Neurology and Psychiatry (NCNP) were retrospectively reviewed in order to obtain data
reflecting the severity and progression of the disease. We also referred to items in the datasheet of the nationwide
registry of dystrophinopathy patients in the Registry of Muscular Dystrophies (Remudy). Items selected for the
registration sheet included age, sex, age at onset, past history and complications, family history, body weight and
height, pathological findings of muscle biopsy, grip power, walking ability, respiratory function, cardiac function,
willingness to join upcoming clinical trials, and participation in patient associations. A copy of the original genetic
analysis report was required of each patient.
Results: We successfully established the Remudy-GNE myopathy. Currently, 121 patients are registered nationwide,
and 93 physicians from 73 hospitals collaborated to establish the registry. The mean age at onset was 27.7 ± 9.6 years,
and 19.8% (24/121) of patients could walk without assistance. Mean presumed durations from onset to use of assistive
devices (cane and/or braces) and a wheelchair, and loss of ambulation were 12.4, 15.2, and 21.1 years, respectively.
Three patients had a past history and/or complication of idiopathic thrombocytopenia. To share the progress of this
study with the community, newsletters were published on a regular basis, and included information regarding new
phase I clinical trials for GNE myopathy. The newsletters also served as a medium to bring attention to the importance
of respiratory evaluation and care for respiratory insufficiency.
Conclusion: The Japanese Remudy-GNE myopathy is useful for clarifying the natural history of the disease and
recruiting patients with genetically-confirmed GNE myopathy for clinical trials.
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GNE myopathy, also known as distal myopathy with
rimmed vacuoles (DMRV), Nonaka myopathy, or her-
editary inclusion body myopathy (hIBM), is an early
adult-onset myopathy with slow progression that prefer-
entially affects the tibialis anterior muscles and commonly* Correspondence: yoshimur@ncnp.go.jp
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article, unless otherwise stated.spares the quadriceps femoris muscles [1,2]. GNE myopathy
is caused by mutations in the GNE gene encoding a bifunc-
tional enzyme [uridine diphosphate-N-acetylglucosamine
(UDP-GlcNAc) 2-epimerase and N-acetylmannosamine
kinase] that catalyzes two rate-limiting reactions in cyto-
solic sialic acid synthesis [3-7]. Oral sialic acid metabolite
supplementation prevents muscle atrophy and weakness
in a mouse model of GNE myopathy [8]. While the in-
cidence of GNE myopathy is unknown, more than 200
patients currently exist in Japan [9].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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their usefulness in obtaining epidemiological data and
patient recruitment for clinical trials [10] Translational
Research in Europe–Assessment and Treatment of
Neuromuscular Diseases (TREAT-MND ALLIANCE),
a research network for neuromuscular disorders, developed
a global database for patients with Duchenne muscular
dystrophy (DMD) [11], spinal muscular atrophy, alpha-
dystroglycanopathy with mutations in FKRP, and dysfer-
linopathy [12]. National registries for other muscular
dystrophies and myopathies also exist. In 2009, we de-
veloped a national registry for neuromuscular diseases
(Registry of MUscular DYstrophy; Remudy. http://
www.remudy.jp/) in Japan in collaboration with the
TREAT-MND ALLIANCE in order to aid in the re-
cruitment of eligible patients for clinical trials, provide
information regarding the natural history and epidemi-
ology of diseases, and serve as a source of information
on current clinical care [13]. Given that GNE myopathy is
quite rare and the fact that clinical trials have already begun
on this disease, the establishment of a patient registry is ur-
gently needed, as it would allow for the early recruitment of
patients in future clinical trials. Moreover, in addition to
contributing to our knowledge on the natural history of
GNE myopathy, accurate medical records also serve as a
medium to judge clinical trial results. Remudy tentatively
registered only male patients with dystrophinopathy.
We intend to expand the registry to include patients
with GNE myopathy.
Here, we describe the development of a national patient
registry for GNE myopathy based on genetic diagnoses,
analyze clinical and genetic characteristics of the disease,
and provide etiological data important for clinical trials.
Methods
Institution, organization, registration method, data
collection, and ethical approval
Remudy is supported by Intramural Research Grants
(23-4/26-7) for Neurological and Psychiatric Disorders
from the National Center of Neurology and Psychiatry
(NCNP). Methodology used to establish the Remudy regis-
try system was described previously [11,13,14]. Registry
information was provided to interested individuals and
their informed consent was obtained. Individuals whose
data were included were informed that inclusion in the
database confers no obligation to the patient, and that
they may be removed from the registry immediately
upon request. They were also told that refusal to partici-
pate would not affect the patient’s subsequent medical
care. This study was approved by the Medical Ethics
Committee of the NCNP. Study objectives, design, risks,
and benefits of participation were explained to all pa-
tients, and their written informed consent was obtained
prior to enrollment.Patients
Patients can join the registry via three routes: the Remudy
homepage, attending specialists of neurology and myology,
and patient associations (the Patient Association of Distal
Myopathy, PADM; and the Japan Muscular Dystrophy
Association, JMDA). This database includes mutation
data confirmed by genetic analysis. Prior to launching
the registry, members of SOCIETAS NEUOLOGICA
JAPONICA (Japanese society of Neurology) were in-
formed about the purpose of the registry, asked to in-
form their patients about the registry, and to cooperate
when patients asked them to confirm medical information
regarding the registry through leaflets.
Structure of the registry form
Based on our review of medical records and prospective
natural history studies of GNE myopathy from the National
Center Hospital of NCNP and questionnaires from previ-
ous studies [15-17], we concluded that walking ability and
respiratory function might be important for evaluating
disease status. Based on clinical information from patients
with GNE and the basic form used in the registry for pa-
tients with dystrophinopathy in Remudy [13], we chose
items required for registration.
Items in the registry form include past history, compli-
cations, family history, disease onset, ambulation status,
results of muscle biopsy, and results of genetic analysis.
Walking capability, grip power, cardiac and respiratory
function, and serum creatinine kinase (CK) levels are
also included in GNE myopathy natural history studies,
given their relevance to the prognosis as well as their
utility as outcome measures. A copy of the original report
of the genetic analysis for GNE is required for registration,
i.e., only patients with a diagnosis confirmed by a genetic
report were included in the registry. Participants with only
single heterozygous mutations in GNE were registered
only when they had pathology results indicating the pres-
ence of rimmed vacuoles on muscle biopsy.
Data collection, curation, and accession
All patient data including clinical and genetic informa-
tion were registered by patients. Each of the attending
neurologists filled in information pertaining to past
medical history, family history, and data from medical
records (biopsy findings, laboratory and physiological
data, and information regarding whether the patient
had the capacity to understand the study objectives).
The patients sent Case Report Forms, along with per-
sonal information (mailing address, phone number,
and e-mail address), consent to use their information
in clinical trials, participation consent for themselves
and their attending physicians, and genetic diagnosis.
As data were extracted from medical records, this
study is a cross-sectional study for the purposes of the
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of the annual data we are currently collecting. After
the patient data were registered, medical and genetic
curators cleaned up “tentative” data. Clinical curators
are neurology specialists in myology at the NCNP, while
genetical curator. is a neurologist and myological researcher
responsible for genetic diagnosis of GNE myopathy at the
NCNP. During the curation process, curators were able to
ask the registrants and their attending neurologists to
double-check the accuracy of information, with the agree-
ment with both patients and their attending neurologists.
As the Remudy-GNE registry utilizes a yearly renewable
system to enable prospective data analysis, we asked regis-
trants to renew their data at least once a year and with any
change in physical status. All patient data provision is vol-
untary and data are not shared with any third party without
the permission of the committee responsible for informa-
tion disclosure. The structure of the Case Report Form and
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Genetic analysis* facility ( )
Complications
Patient status
Body weight and height
Age and symptoms at onset
Walking capability and wheelchair use
Grip power
Respiratory function (VC,%VC, FVC,%FVC,
mechanical support)
Cardiac functions (EF, ES)
Creatine kinase level
Gray cells are for patients to fill out, and white cells are to be filled out
by physicians.
VC: vital capacity, FVC: forced vital capacity, EF: ejection fraction, FS:
fraction shortening.Medical record analysis
Medical records of all patients with genetically-confirmed
GNE myopathy in the National Center Hospital of NCNP
were retrospectively reviewed by M. MY.
Data analysis
Data were summarized using descriptive statistics, including
mean, standard deviation (SD), median, range, frequency,
and percentage. Each variable was compared using a t-test.
Spearman’s rank correlation coefficients were used to deter-
mine associations between variables. Time from disease
onset to walking with assistance, time from disease onset to
wheelchair use, and time from disease onset to loss of
ambulation were evaluated using the Kaplan–Meier
method. All statistical analyses were performed using SPSS
for Macintosh (Version 18; SPSS Inc., Chicago, IL).
Results
General characteristics at study entry
As of the end of October 2013, a total of 121 Japanese
participants with GNE myopathy (55 men and 66 women)
had registered (Table 2). Mean ages at data collection and
disease onset were 44.9 ± 13.2 years (mean ± SD) (median,
43 years; range, 21–85 years) and 27.9 ± 9.6 years (median,
26 years; range, 12–61 years), respectively. The registry
included participants from throughout Japan (38/47
prefectures) who were recruited through a collabor-
ation with 92 attending physicians from 73 institutes
(Figure 1). Among the 52 genetically-confirmed patients
with GNE myopathy who had visited NCNP, 32 (62%)
participated in the patient registry.
GNE mutations
Thirty-nine of 121 participants (32.3%) harbored a
homozygous mutation in GNE and 64.5% (78/121) had
a compound heterozygous mutation. Only single het-
erozygous mutations were found in four (3.3%) partici-
pants (Additional file 1: Table S1). Among participants
with a homozygous mutation, 82% (32/39), 8% (3/39),
and 5% (2/39) harbored p. V572L, p. C13S, and p. M712T
mutations, respectively. Homozygous mutations of p. D176V
and A630T were identified in only one participant.
Of those carrying two heterozygous mutations, 31%
(24/78) had p. D176V/p. V572L mutations, while the
remaining participants carried other combinations of
mutations. The frequency of the p. V572L mutation
was 46% (106/230), p. D176V was 25% (58/230), p. C13S
was 4% (9/230), and each of p. M712T and p. A631V
was 2% (4/230) (Additional file 2: Table S2). One pa-
tient with a single heterozygous mutation visited the
NCNP Hospital, so we reviewed his medical records
and noted that he was showing clinical symptoms of
GNE myopathy as well as pathological features.
Table 2 Participant characteristics
n % Mean ± SD Minimum Median Maximum
Age 121 100 44.8 ± 13.0 21 43 85
Sex Male 55 44
Female 66 55
Age at onset 121 100 27.7 ± 9.6 15 26 61




Walking capability Ambulant without assistance 24 20
Ambulant with assistance 45 37
Non-ambulant 52 43
Wheelchair use Never 43 36
Part-time 28 23
Full time 50 41
Respiratory function (%FVC) Performed 79 65 88.4 ± 23.7 16.4 92.8 130
Not performed 42 35
Normal (FVC≥ 80%) 26 33*
Decreased 53 67*
Nocturnal NPPV 2 2
Cardiac function Performed 35 29
(EF, ES) Not performed 86 71
Normal 35 100*
Decreased 0 0*
Grip power (kg) Performed 96 79 5.5 ± 7.2 0 2.9 30
Not performed 25 21
Grip power = 0 36 38*
CK (Iu/L) Performed 120 99 357.8 ± 209.0 11 209 459
Not performed 1 1
*ratio of examined/performed.
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Thirty-nine of 121 participants (32.2%) had a family history
of GNE myopathy. Eleven of 121 (9.1%) were from consan-
guineous parents. Among the 39 participants with homozy-
gous mutations, 9 (23.1%) had consanguineous parents; 2
participants with a compound heterozygous mutation were
from one family, as their mothers and fathers were siblings
(i.e., these participants were double cousins).
Complications and past medical history
A detailed review of medical histories revealed that three
participants had hypertension, two had diabetes mellitus,
and two had hyperlipidemia. Two participants were di-
agnosed with obstructive sleep apnea syndrome, one of
whom required continuous positive airway pressure.
Atopic dermatitis and mastopathy were seen in one
participant each. Of note, three participants had a pasthistory of idiopathic thrombocytopenia (ITP). We obtained
additional medical histories for three patients with histories
of ITP. All three had experienced bleeding symptoms
and had undergone intravenous and/or oral steroid
therapy. Two of them were hospitalized for this ther-
apy. Patients were unable to recall the platelet count or
platelet-associated IgG (PAIgG). However, two patients
presented with low platelet counts, one of whom was
PAIgG-positive at the time of registration.
To clarify whether patients with GNE myopathy had
thrombocytopenia, we reviewed blood counts of those with
genetically-confirmed GNE myopathy. Among 52 patients
with GNE myopathy in NCNP (including the three partici-
pants with a past history of ITP), mean platelet counts were
22.1 × 104/μl (normal range: 15–35 × 104/μl). Importantly,
three patients, including two with a past history of ITP, had
decreased platelet counts of 9.5, 10.3, and 7.1 × 104/μl, and
Figure 1 Participant distribution. Participants were distributed throughout Japan (38/47 prefectures), and 92 physicians in 73 institutes agreed
to contribute to the registry.
Figure 2 Initial symptoms. The most common initial symptom
was walking slowness and/or difficulty (54%). Difficulty lifting toes
(23%) due to foot drop was the third most common symptom,
whereas certain populations had difficulty lifting heels (4%). Some
participants had weakness in the hands and/or fingers (4%) and
difficulty lifting the neck (2%) from the time of disease onset. The
number of participants with the indicated symptoms are shown.
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p. V572L, and p. R8X/p. V572L.
Onset and ambulation status
Mean age at disease onset for the 121 registered participants
was 27.7 ± 9.6 years (median, 27.5 years; interquartile range,
15–61). Initial symptoms were walking slowness and/
or difficulty (65/121, 54%), stumbling (50/121, 41%),
difficulty lifting toes (28/121, 23%), difficulty climbing
stairs (12/121, 12%), difficulty running (9/121, 7%), difficulty
lifting heels with a weakness of hands and/or fingers
(5/121, 4%), and difficulty in thigh adduction and lifting the
neck (2/121, 2%) (Figure 2). As weakness in the anterior
parts is thought to be more prominent than that in the pos-
terior calf in GNE myopathy, we reviewed medical records
of the 62 patients who received treatment at NCNP hospi-
tals and identified two patients for whom the first symptom
was “difficulty lifting heels.” Prominent calf weakness
(MMT ankle dorsoflexion 5, plantar flexion 2) was evident
in these patients, along with marked fat replacement in the
calf muscles (Additional file 3: Figure S1).
Table 2 summarizes the clinical characteristics of partic-
ipants included in the registry. A total of 20% (24/121)
of participants were ambulant without assistance, 37%
(45/121) required assistance (e.g., canes and/or braces),
and 43% (52/121) had lost ambulation. Mean age at loss of
ambulation was 35.4 ± 11.3 years. Kaplan–Meier analysis
revealed a median time from disease onset to walking with
assistance of 8.9 years (95%CI, 6.3-9.7), from disease onsetto wheelchair use of 14.0 years (95%CI, 11.8-16.2), and
from disease onset to loss of ambulation of 21.0 years
(95%CI, 15.4-26.6) (Table 3).
Body Mass Index (BMI)
BMI of 65/121 (54%) participants were within the normal
range in Japan (18.5-25) [13], whereas 36/121 (30%) were
under the normal range and 20/121 (16%) were obese.
Among the 20 obese participants, two were severely
obese (>35%) by Japanese standards [18]. Mean BMI of
Table 3 Analysis of time from disease onset to walking with assistance, wheelchair use, and ambulation loss
Incidence-free proportion
Mean SD 95% CI Median Interquartile range 95% CI 10 years 20 years
Aassistive device use 12.4 1.3 10.0 14.9 8.0 5.0-13.0 6.3 9.7 0.38 0.18
Wheelchair use 15.2 0.8 13.6 16.9 14.0 8.0-22.0 11.8 16.2 0.64 0.29
Loss of ambulation 21.1 1.4 18.3 23.8 21.0 11.0-37.0 15.4 26.6 0.78 0.51
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participants, although the difference was not significant
(non-ambulant 22.0 ± 4.3 vs. ambulant 20.6 ± 4.6, p = 0.077).
The number of participants who were underweight was
greater than that of the normal population. Proportions
of men and women who were underweight were 18.2%
(n = 11; 16.4 ± 1.9; median, 17.2; range, 12.1-18.5) and
34.8% (n = 23; 16.9 ± 1.3; median, 17.1; range, 13.6-18.4),
respectively, and were 4.7% and 9.1% among healthy men
and women, respectively. There were fewer obese partici-
pants compared to the normal population (Figure 3) [18].
We identified no significant correlations between BMI and
other items, with the exception of age (r = 0.291, p = 0.001).
Cardiopulmonary function
Information on pulmonary and cardiac function was
available for 65% (79/121) and 34% (41/121) of participants,
respectively. Of those examined, 33% (26/79) had respira-
tory dysfunction [% forced vital capacity (%FVC < 80)], and
two were using nocturnal non-invasive positive pressure
ventilation (NPPV).%FVC was significantly correlated
with disease duration (ρ = 0.479, p < 0.01) and serum CK
levels (ρ = 0.573, p < 0.01). None of the participants who
underwent ultrasound cardiographic examination had
cardiac dysfunction (ejection fraction, 50-82%; fraction
shortening (FS), 25-50%). Mean serum CK level was
459.1 ± 355.0 IU/L (median, 202; range, 11–3133).
Bulletin, newsletter, and facilitation of participant
recruitment through GNE myopathy registry
We have been publishing bulletins every three months
and sending them to participants and doctors who join
Remudy. The bulletin includes useful information regarding
clinical care, translational medicine, and clinical trials, as
well as articles introducing specialists and specialized hospi-
tals for muscle diseases. These contents are also available
on the Remudy homepage. Participant recruitment has also
started for additional phase I clinical trials via the Remudy
GNE myopathy registry homepage [19].
Discussion
To our knowledge, we describe the first patient registry
for GNE myopathy in the world. This registry will con-
tribute to the analysis of the natural history of GNE
myopathy and aid in the recruitment of participants
for clinical trials.Participants with GNE myopathy were widely distributed
throughout Japan, with 1.7 patients per hospital and 1.3 pa-
tients per physician in this study. In contrast, there were 5.8
patients with dystrophinopathy (60% of patients with DMD)
per hospital and 3.6 per physician in the dystrophinopathy
registry. Thus, while patients with GNE myopathy appeared
to be dispersed throughout Japan, patients with dystrophi-
nopathy were concentrated in specialized hospitals, given
the need for cardiopulmonary care. This indicates that
Remudy may serve a very important role in disseminating
clinical information to patients with GNE myopathy and
their doctors who are dispersed throughout Japan. The pa-
tient registry is also useful in that it allows for recruiting
patients and resolving data deviation in comparison with
analyses by isolated institutions. For example, the age at
disease onset in the Remudy-GNE cohort was later than
that determined from an analysis of medical records at
the NCNP Hospital (26.8 ± 9.0 years). In our previous
questionnaire-based study of core muscle disease center
patients, we reported a median proportional duration
from disease onset to walking with assistance, wheelchair
use, and loss of ambulation of 7.0 ± 0.4 years, 11.5 ± 1.2 years,
and 17.0 ± 2.1 years, respectively [14], which were all
shorter than the durations determined in the present
study. We speculate that this discrepancy may reflect
the more advanced disease status of patients at neuro-
muscular disease-specialized center hospitals. Future
improvement of Remudy-GNE registry may conclude
why these bias were found in this study.
Three (2.5%) of 121 participants had a past history of ITP
in our cohort. As the total number of patients with ITP is
estimated to be 20,000 in Japan, with an annual occurrence
of 3,000 [20], and the Japanese population was 1.27 × 108
in 2013, the prevalence of ITP is expected to be 15.7 per
100,000 (1.57 × 10−2%). This means that the frequency of
ITP among patients with GNE myopathy is 158 times
higher than the general population, at least in our cohort.
UDP-GlcNAc 2-epimerase is a major determinant of
cell surface sialylation in human hematopoietic cell lines
and a critical regulator of the function of specific cell sur-
face adhesion molecules [6]. Thus, alterations in platelets
may occur in patients with GNE myopathy. For example,
platelets from patients with ITP show increased electro-
phoretic mobility, reflecting increased sialic acid content
[21]. Among the three participants with decreased platelet
counts, two had ITP, raising the possibility of a causal
Figure 3 BMI of participants and the general adult Japanese population (aged >20 years). More registry participants were underweight
compared to the general population. Proportions of underweight participants were 18.2% and 34.8% for men and women, respectively, and 4.7%
and 9.1% for healthy men and women, respectively. There were fewer obese participants relative to the general population. a. black column:
participants, open column: general Japanese population. b. gray column: participants, diagonal column: general Japanese population.
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underlying mechanisms are unclear and further studies
would be necessary to address this issue. Of note, however,
this information was obtained based on self-report by
patients and/or their families. Thus, the accuracy of
the diagnosis is unclear.
It is noteworthy that in some patients, initial symptoms
were difficulty lifting heels, but not toes. It is conventionally
thought that the initial symptom of GNE myopathy is “foot
drop,” as tibialis anterior muscles are strikingly affected.
Our study suggests that patients whose symptoms start
with calf muscle weakness may have GNE myopathy. It
is also surprising that some patients had neck and finger
weakness from disease onset, despite GNE myopathy
being known as “distal myopathy.” Thus, GNE myopathy
appears to be associated with more phenotypes than
expected. However, we are not confident that all patients
who chose “difficulty lifting heels” exhibited prominent
calf weakness in reality as well, i.e., they experienced
greater calf weakness relative to tibialis anterior muscle
weakness. This is one limitation of using medical histories
and a registration system to collect patient data.
Although we previously reported respiratory dysfunction
associated with GNE myopathy [15], 35% of participants
in the present study were not examined for respiratory
function, indicating that many physicians and neurolo-
gists are unaware of the clinical significance of respira-
tory function in the context of this disease. Although we
did not observe any cases of cardiac dysfunction, it may
occur in older patients or those with advanced disease.
Supporting this is evidence from a study showing that
20% of GNE myopathy mice develop fibrosis in cardiac
tissue after 30 weeks of age, with some exhibiting marked
endomysial fibrosis, amyloid deposition, and occasionally
rimmed vacuoles in cardiomyocytes [8]. This suggests that
the risk of cardiopulmonary dysfunction in GNE myop-
athy should be considered.In this study, four participants harbored single heterozy-
gous mutations, although they exhibited clinicopathologi-
cally definite findings of GNE myopathy. The age at disease
onset did not significantly differ between homozygotes
and compound heterozygotes. Given that we limited our
analysis to all exons and their flanking introns, it is possible
that single heterozygotes who exhibited features of GNE
myopathy may have mutations in other genomic regions
of GNE. Yet, in the absence of data using disease-specific
biomarkers, it is difficult to distinguish whether these
participants had other myopathies and carried a single
heterozygous mutation in the GNE gene.
Among registry participants, 46% were in the abnormal
range of BMI, and the number of underweight participants
was markedly higher in both men and women, compared
to the normal population. None of the participants or
patients of NCNP had dysphagia or other medical prob-
lems which might promote weight loss. The BMI of
non-ambulant patients tended to be higher than ambulant
patients, suggesting that muscle atrophy itself did not cause
weight loss. Mechanisms underlying the weight changes
may differ from those observed in muscular dystrophy such
as DMD [22] or myotonic dystrophy [23], given that obesity
was not an issue with most patients with GNE myopathy.
It is not clear whether being underweight is beneficial rela-
tive to having normal weight in these patients. Prospective
analyses will be needed to reveal the relationship between
motor function prognosis and body weight.
This study has some limitations worth noting. First, we
could not unify the method of grip power assessment.
Second, we relied on descriptions of motor function as a
crude benchmark for designing clinical trials. Finally, we
could not address phenotype-genotype correlations in
more depth than was previously reported [9], given the
limited number of homozygote patients harboring
mutations other than V572L. A larger cohort will be
needed to address genotype-phenotype correlations.
Mori-Yoshimura et al. Orphanet Journal of Rare Diseases 2014, 9:150 Page 8 of 9
http://www.ojrd.com/content/9/1/150Similar to our collaborations involving the dystrophi-
nopathy registry, we are currently in discussions to
harmonize the international registry of GNE myopathy
of the TREAT-NMD ALLIANCE [ClinicalTrials.gov
Identifier NCT01784679, http://www.treat-nmd.eu/gne/
patient-registries/international-registry/] (GNE-DMP), in
hopes of gaining further insights into the disease. There
are two major differences between GNE-DMP. First, as
the Remudy aims to establish registration according to gen-
etic diagnosis, inclusion criteria for genetics-based longitu-
dinal natural history studies employing the Remudy-GNE
registry require genetic diagnosis (including single heterozy-
gote). Second, we are the only Japanese language registry
system. Japan has one of the largest patient groups with
GNE myopathy in the world [24]. It is important that
patients with this disease receive information in their
native language, and that domestic information is sup-
plied for the purpose of Japanese patient accession. Har-
monisation would be conducted in order to avoid
duplication and double registration of GNE patients
while providing the same benefits and opportunities to
patients, regardless of where they live. Both registries
are similar in their processes utilized for data collection
as well as their fundamental ideas regarding the regis-
tries, and thus we hope to merge the two registries at
some point. According to a tentative agreement, the
Remudy-GNE will remain the primary entryway into
the international registry as well as serve as the contact
site for Japanese patients, and only anonymous data
will be stored in the joint data set. Strategies for
merging the two registries are currently under
consideration.
Our Japanese registry and the TREAT-MND ALLIANCE
registry work in close collaboration, and will serve as
irreplaceable infrastructures that accelerate research,
therapy development, and trial readiness, in addition
to increasing opportunities for collaboration and im-
proving global patient care.
Conclusion
The patient registry for GNE myopathy in Japan is useful
for gaining a better understanding of the disease, and
recruiting patients with genetically-confirmed GNE
myopathy for upcoming clinical trials. Further advances and
insights can be expected through a soon-to-be-launched
international GNE myopathy registry.
Additional files
Additional file 1: Table S1. Genotyping. ED = Glucosamine
(UDP-N-acetyl)-2-epimerase domain, KD = N-acetylmannosamine
kinase domain. There were more participants who were either
homozygous for p.V572L or heterozygous for p.D176V/p.V572L
compared to those with other mutations. Although p.D176V was thesecond most frequent mutation, there was only one participant in
the registry who was homozygous for p.D176V.
Additional file 2: Table S2. Allelic frequency. p.V572L was the most
frequent mutation.
Additional file 3: Figure S1. Muscle CT of 29 year-old GNE myopathy
patient who reported difficulty lifting his heels as one of the first symptoms.
Ankle plantar flexion (MMT 2) was prominently impaired (MMT5), and
muscle CT revealed that fatty replacement and atrophy were far more
prominent in the calf than the anterior part of the lower legs.
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